75/76 Wimpole Street
London W1G 9RT
United Kingdom
44 20 8004 0270
https://www.akaritx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 15
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Ms. Rachelle Suzanne Jacques | President, CEO & Director | 1.38M | N/D | 1971 |
Ms. Wendy F. DiCicco CPA | Interim Chief Financial Officer | N/D | N/D | 1967 |
Ms. Melissa Bradford-Klug | Chief Operating Officer | N/D | N/D | 1970 |
Dr. Miles Nunn | Chief Scientific Officer | N/D | N/D | 1969 |
Dr. John F. Neylan III, M.D. | Executive VP & Chief Medical Officer | N/D | N/D | 1953 |
Ms. Beth-Anne Lang | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
Annie Mack | Financial Controller | N/D | N/D | N/D |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.
La calificación ISS Governance QuickScore de Akari Therapeutics, Plc a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.